Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Rotterdam – page 12

809 clinical trials in Rotterdam, The Netherlands across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Rotterdam at a glance
809
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

809 trials in Rotterdam

Open in trial search

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AstraZeneca AB

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Revolution Medicines Inc.

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibuzatrelvir
  • Sponsor:Pfizer Inc.

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Fungal infection+3

Recruiting

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Basilea Pharmaceutica International AG Allschwil

Neoplasm

Recruiting

Study of BMS-986482 alone or with nivolumab, relatlimab or bevacizumab in patients with advanced solid tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Evaluation of Hydrocortisone, Octreotide, and Teres Ligament Patch Combination to Prevent Complications After Pancreatoduodenectomy in Patients with Pancreatic Head Cancer or IPMN

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Amsterdam UMC Stichting

Study on Ersodetug for Patients with Uncontrolled Low Blood Sugar Due to Tumor-Related High Insulin Levels

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Anti-(Insulin Receptor) Human Monoclonal Antibody
  • Sponsor:Rezolute Inc.

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study on the Safety and Effects of DNL593 for Patients with Frontotemporal Dementia

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:DNL593
  • Sponsor:Denali Therapeutics Inc.

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Rotterdam

What the registry says about research in the country

01 Neurology and Mental Health

Innovative research focusing on frontotemporal dementia treatments and management of migraine in relation to obesity. Studies include evaluation of new therapeutic compounds and their effects on neurological conditions.

  • Dementia Treatment Studies
  • Migraine Management Research
  • Neurological Disease Interventions

Research aims to improve patient outcomes through targeted therapeutic approaches and innovative treatment methods.

02 Oncology and Cancer Research

Comprehensive studies targeting various forms of cancer, including advanced gastric cancer and bladder cancer. Research includes innovative imaging techniques and combination therapy approaches.

  • Gastric Cancer Treatment
  • Cancer Immunotherapy
  • Diagnostic Imaging Studies

Focus on developing more effective treatment strategies and improving diagnostic capabilities.

03 Metabolic and Endocrine Disorders

Clinical trials addressing obesity and related metabolic conditions, including innovative approaches to weight management and metabolic disease treatment. Studies evaluate new therapeutic options for thyroid disorders.

  • Weight Management Therapies
  • Thyroid Disease Treatment
  • Metabolic Disease Research

Research focuses on developing effective treatments for complex metabolic conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.